Romain‐David Seban

Author

Romain‐David Seban

Inserm ORCID

Also Known As

R. D. Seban, R. Seban, R.-D. Seban, R.D. Seban, Romain-David Seban, Romain‐David Seban, Seban, Romain-David

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Inserm Institut Curie Université Paris-Saclay Institut Gustave Roussy Columbia University Irving Medical Center

About

Romain‐David Seban is an author at Inserm specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	603
2	Immunology	6	6	328
3	Health Sciences	5	5	269
4	Pathology	3	3	181
5	Clinical Immunology	1	1	13

Romain‐David Seban

Publications

Citations

H-Index

Page 1

	Year	Citations
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors Romain‐David Seban, Laura Mezquita, Arnaud Berenbaum, European Journal of Nuclear Medicine and Molecular Imaging Health SciencesOncologic ImagingMedicineImmune Checkpoint InhibitorsPathology	2019	125
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics Romain‐David Seban, John S. Nemer, Aurélien Marabelle, European Journal of Nuclear Medicine and Molecular Imaging Cancer ImmunosurveillanceAnti-pd1 ImmunotherapyMedicineBiomarker TargetMelanoma	2019	123
<sup>18</sup>F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor Laurent Dercle, Romain‐David Seban, Julien Lazarovici, Journal of Nuclear Medicine	2017	114
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0 Egesta Lopci, Rodney J. Hicks, Antonia Dimitrakopoulou‐Strauss, European Journal of Nuclear Medicine and Molecular Imaging	2022	96
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 Romain‐David Seban, Antoine Moya‐Plana, Lara Antonios, European Journal of Nuclear Medicine and Molecular Imaging Cancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsMelanomaImmunology	2020	73
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy Laurent Dercle, Samy Ammari, Stéphane Champiat, European Journal of Cancer Prognostic EvaluationPrognostic BiomarkersMedicinePrognosisImmune Checkpoint Inhibitor	2016	67
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy Romain‐David Seban, Jean‐Baptiste Assié, Etienne Giroux‐Leprieur, Lung Cancer InflammationBiomarker (Medicine)Prognostic BiomarkersMedicinePrognostic Value	2021	50
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab Aiping Chen, Fatima‐Zohra Mokrane, Lawrence H. Schwartz, Journal of Nuclear Medicine	2019	45
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma Laurent Dercle, Samy Ammari, Romain‐David Seban, European Journal of Cancer Lymphoid NeoplasiaMedicineImmunologyTumor ImmunityImmune Surveillance	2018	39
Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer Romain‐David Seban, Roman Rouzier, Aurélien Latouche, European Journal of Nuclear Medicine and Molecular Imaging Prognostic BiomarkersBreast OncologyOncologyOncologic ImagingSpleen Metabolism	2021	37

Page 1